SFPIA
SAGE

Stevens First Principles Investment Advisors’s Sage Therapeutics SAGE Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-200
Closed -$12K – 177
2015
Q4 		$12K Sell
200
-500
-71% -$24.8K 0.01% 152
2015
Q3 		$30K Buy
+700
New +$43.1K 0.02% 138

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Stevens First Principles Investment Advisors's SAGE Position: Q1 2016 in Review

Stevens First Principles Investment Advisors sold out of Sage Therapeutics (SAGE) in Q1 2016, closing a stake of 200 shares — an estimated $12K sold.

Stevens First Principles Investment Advisors first reported a position in SAGE in Q3 2015 and held it in 2 quarters. The position peaked at $30K in Q3 2015. 143 funds tracked by Wall St. Rank hold SAGE as of Q1 2016.

  • Stevens First Principles Investment Advisors reported no remaining Sage Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Stevens First Principles Investment Advisors sold 200 Sage Therapeutics shares in Q1 2016, an estimated $12K.
  • Stevens First Principles Investment Advisors first reported a position in Sage Therapeutics in Q3 2015 and held it in 2 quarters.
  • Stevens First Principles Investment Advisors's Sage Therapeutics position peaked at $30K in Q3 2015.
  • 143 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2016.

Based on Stevens First Principles Investment Advisors's 13F filing for Q1 2016, filed 13 May 2016.